Torre C, et al. - In this inception cohort study involving 1,328 candidates, researchers determined the frequency and the time-course profile of adverse drug events correlated with new glucose-lowering drugs in daily practice and analyzed factors potentially related to these events. Eligible for inclusion are adults with T2DM starting a dipeptidyl peptidase-4 inhibitor, a glucagon-like peptide-1 receptor agonist or a sodium-glucose co-transporter-2 inhibitor. To explore potential factors related to adverse drug events, Cox models were used. According to findings, an adverse drug event was reported by more than two-fifths of participants. Dipeptidyl peptidase-4 inhibitors have resulted in the highest percentage of unlabelled adverse drug events. Adverse drug event latency time data display that from the start of therapy, counselling and adverse drug event management should be handled proactively. Further emphasis should be focused on prevalent new users of glucose-lowering medications, who were more complex participants in this research with respect to T2D disease as they were more likely to report an adverse drug event than the incident new users.